Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Inclusion Criteria:

- enrolled in the ADRN Registry study.

- active, mild to severe AD (lesions present) with or without a history of eczema
herpeticum or who are non-atopic as diagnosed using the ADRN Standard Diagnostic
Criteria.

- willing to sign the informed consent form prior to initiation of any study procedure.

Exclusion Criteria:

- pregnant or lactating. Women of child bearing potential must avoid becoming pregnant
(use of an effective method of contraception or abstinence) for the duration of their
participation in the study.

- have a known allergy to any component of the Fluzone® Intradermal or Fluzone®
(Intramuscular) vaccines, including egg protein, or have had a severe allergic
reaction to a previous dose of any influenza vaccine.

- known or suspected congenital or acquired immunodeficiency or who have had
immunosuppressive therapy (excluding steroids) such as anti-cancer chemotherapy or
radiation therapy within the preceding 6 months.

- received systemic steroid therapy for 2 or more weeks at a dose ≥ 20 mg/day
prednisone equivalent within 1 month prior to the day of vaccination or expect to
receive within 3 weeks post-vaccination.

- received a cumulative dose of inhaled and/or intranasally administered
corticosteroids ≥ 880 mcg/day fluticasone equivalent for 2 or more weeks within 1
month prior to the day of vaccination or expect to receive within 3 weeks
post-vaccination.

- a chronic illness, including but not limited to, cardiac, renal, or auto-immune
disorders, or diabetes, at a stage that could interfere with study conduct or
completion, based on the opinion of the Investigator. Asthma and underlying allergic
conditions such as allergic rhinitis are not exclusionary.

- a neoplastic disease or any hematologic malignancy. Participants who have been
disease free for at least six months will not be excluded.

- participated in another clinical trial investigating a vaccine, drug, medical device,
or a medical procedure in the four weeks preceding the study vaccination or who plan
to participate in another clinical trial during the present study period.

- any skin disease other than AD that might compromise the stratum corneum barrier
(e.g., bullous disease, psoriasis, cutaneous T cell lymphoma [also called Mycosis
Fungoides or Sezary syndrome], dermatitis herpetiformis, Hailey-Hailey, or Darier's
disease).

- received blood or blood-derived products that might interfere with the assessment of
immune response in the past 3 months prior to vaccination or who plan to receive such
products during the study period.

- received previous vaccination (Fluzone® or another vaccine) against influenza in the
past 6 months prior to vaccination.

- received any other live vaccines within 4 weeks or inactivated vaccines within 2
weeks prior to study vaccination or who plan to receive any vaccination during the
study period.

- thrombocytopenia or bleeding disorder in the 3 weeks preceding vaccination.

- personal or family history of Guillain-Barré Syndrome.

- a first degree relative already enrolled in the study.

- determined to be not eligible based on the opinion of the Investigator.